hVIVO Holdings Ltd is a United Kingdom-based company. The Company is engaged in sciences business pioneering a technology platform of human disease models to accelerate drug discovery and in respiratory and infectious diseases, including flu, respiratory syncytial virus (RSV), asthma and common cold.

Employees

Sector

Healthcare Facilities & Services

More about the company

Delayed London S.E.			5-day change	1st Jan Change
- ^GBX	-.--%		+18.92%	+41.94%

05-07	HVIVO Secures GBP6 Million Deal to Run Influenza Human Challenge Trial for Monoclonal Antibody	MT
04-22	HVIVO to Run Late-stage Human Challenge Trial for ILiAD's Whooping Cough Vaccine Candidate	MT

Market Cap	13.8M 18.82M 16.13M 15.11M 26.05M 1.79B 26.31M 178M 69.4M 905M 70.67M 69.13M 3B	P/E 2023	7.02x	P/E 2024	10.6x
Enterprise Value	-17.47M -23.83M -20.42M -19.13M -32.98M -2.27B -33.3M -226M -87.84M -1.15B -89.46M -87.51M -3.8B	EV / Sales 2023	-0.19x	EV / Sales 2024	-0.28x
Free-Float	91.04%	Yield 2023	1.21%	Yield 2024	1.21%

05-07	HVIVO Secures GBP6 Million Deal to Run Influenza Human Challenge Trial for Monoclonal Antibody	MT
04-22	HVIVO to Run Late-stage Human Challenge Trial for ILiAD's Whooping Cough Vaccine Candidate	MT
04-15	HVIVO Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-14	Hvivo plc Signs Clinical Trial Agreement with Traws Pharma	CI
04-14	HVIVO to Run Phase 2a Influenza Challenge Trial for Traws Pharma's Antiviral Candidate	MT
25-09-23	HVIVO Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-29	Hvivo Names New Nonexecutive Chairman	MT
25-04-10	HVIVO Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-02-27	Hvivo Buys UK's Cryo-Store in GBP3 Million Deal	MT
25-02-17	Hvivo Wins GBP2 Million Contract for Human Metapneumovirus Characterization Study	MT
25-01-27	HVIVO to Conduct Late-stage Trial for Whooping Cough Vaccine	MT
25-01-21	Hvivo Lands GBP3 Million Lab Services Deal in US	MT
24-12-10	HVIVO Bags GBP12 Million Contract for RSV Clinical Trials	MT

25-02-04	Inhalon Biopharma Announces First-of-its-Kind Inhaled Antibody Treatment for RSV to Enter Human Clinical Trials	AQ
24-04-09	HVIVO achieves record revenue and initiates dividend policy following successful year	AQ
24-02-20	HVIVO chairman Cathal Friel says he remains committed to hVIVO following share sale	AQ
24-01-02	HVIVO secures Ã‚£6.3 million challenge contract	AQ
23-12-13	HVIVO secures fresh contract to round out "wonderful" year	AQ

hVIVO plc Stock

Stocks

HVO

GB00B6ZM0X53

Healthcare Facilities & Services

Valuation: hVIVO plc

Latest news : hVIVO plc

Press Releases: hVIVO plc

News in other languages: hVIVO plc

Managers and Directors: hVIVO plc

Latest insider transactions

Other Healthcare Facilities & Services

Financials

Company Profile

21-02-17	WDH/Britische Wissenschaftler wollen Freiwillige mit Corona infizieren
20-09-25	Absichtliche Corona-Infektionen: Ein guter Weg zum Impfstoff?

Manager	Title	Age	Since
Mohammed Khan CEO	Chief Executive Officer	57	2022-01-31
Stephen Pinkerton DFI	Director of Finance/CFO	63	-
Thomas Andreas Forst CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Cathal Friel CHM	Chairman	62	2020-03-31
Brendan Buckley BRD	Director/Board Member	76	-
Mohammed Khan BRD	Director/Board Member	57	2022-01-31

Date	Insider	Type	Quantity	% Market Cap.
10/11/24	Yamin Khan	Free	4,606,794	5.5106%
6/14/23	Yamin Khan	Buy	13,526	0.0162%
2/6/23	Yamin Khan	Free	7,227,273	8.6452%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HVIVO PLC	-.--%	+18.92%	-	-	18.04M
CVS HEALTH CORPORATION	-1.03%	-1.86%	+30.80%	+38.35%	120B
HCA HEALTHCARE, INC.	-0.31%	+3.95%	+6.26%	+56.61%	92.93B
FRESENIUS SE & CO. KGAA	-0.48%	-1.49%	-3.46%	+57.13%	30.26B
QUEST DIAGNOSTICS INCORPORATED	-0.22%	+3.08%	+36.31%	+83.95%	26.92B
TENET HEALTHCARE CORPORATION	-1.36%	+1.50%	+52.17%	+269.48%	22.43B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+1.13%	+4.20%	-2.87%	-5.61%	22.19B
REDE D'OR SÃO LUIZ S.A.	+2.52%	+7.74%	-5.86%	+21.02%	14.64B
FRESENIUS MEDICAL CARE AG	+0.15%	-0.88%	-7.52%	-8.94%	12.46B
DAVITA INC.	+0.35%	-0.69%	+28.65%	+75.61%	11.26B
Average	+0.06%	+3.84%	+14.94%	+65.29%	35.35B
Weighted average by Cap.	-0.38%	+2.42%	+18.14%	+58.94%

	2023	2024
Net sales	56.04M 76.41M 65.48M 61.35M 106M 7.28B 107M 724M 282M 3.68B 287M 281M 12.17B	62.72M 85.52M 73.28M 68.67M 118M 8.15B 120M 810M 315M 4.11B 321M 314M 13.62B
Net income	16.11M 21.97M 18.83M 17.64M 30.41M 2.09B 30.71M 208M 81.01M 1.06B 82.5M 80.7M 3.5B	10.65M 14.52M 12.45M 11.66M 20.1M 1.38B 20.3M 138M 53.55M 699M 54.53M 53.34M 2.31B
Net Debt	-24.44M -33.33M -28.56M -26.76M -46.13M -3.18B -46.58M -316M -123M -1.6B -125M -122M -5.31B	-31.28M -42.65M -36.54M -34.24M -59.03M -4.07B -59.61M -404M -157M -2.05B -160M -157M -6.79B